Nabriva Therapeutics AG ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.1 |
Market Cap |
$176.86 M |
Shares Outstanding |
72.78 M |
Public Float |
45.37 M |
Address |
Leberstrasse 20 Vienna Wien (Vienna) 1110 Austria |
Employees | - |
Website | http://www.nabriva.com |
Updated | 07/08/2019 |
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans. It develops intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia and intends to develop lefamulin for additional indications other than pneumonia. |